Literature DB >> 19895957

Traumatic brain injury: neuroprotective anaesthetic techniques, an update.

Nasser A Tawfeeq1, Mohammed M Halawani, Khulood Al-Faridi, Wa'el A Aal-Shaya, Wa'el S Taha.   

Abstract

Traumatic brain injuries remain an area of great challenge to both neurosurgeons and neuroanaesthesiologists. The management of these injuries starts at the scene of the accident. However, strategies for preventing secondary brain injury and its sequelae are continuing to evolve. These strategies include the use of pharmacological and nonpharmacological techniques. Preventing hypoxia and the use of hypertonic saline have been shown to have favourable results on the outcome of these injuries. The use of isoflurane has been shown to have a neuronprotective effect. Propofol is thought to be the future drug of choice because of its neuroprotective properties, although these still need to be further proven through research. In this review an understanding of the pathophysiology of traumatic brain injury will be outlined in order to understand the effects of pharmacological and nonpharmacological agents on secondary brain injury.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19895957     DOI: 10.1016/j.injury.2009.10.040

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  3 in total

Review 1.  Animal models of closed-skull, repetitive mild traumatic brain injury.

Authors:  Wouter S Hoogenboom; Craig A Branch; Michael L Lipton
Journal:  Pharmacol Ther       Date:  2019-02-26       Impact factor: 12.310

Review 2.  [Acute treatment of patients with severe traumatic brain injury].

Authors:  T A Juratli; S E Stephan; A E Stephan; S B Sobottka
Journal:  Anaesthesist       Date:  2015-02       Impact factor: 1.041

3.  Propofol ameliorates calpain-induced collapsin response mediator protein-2 proteolysis in traumatic brain injury in rats.

Authors:  Yun Yu; Min-Yu Jian; Yun-Zhen Wang; Ru-Quan Han
Journal:  Chin Med J (Engl)       Date:  2015-04-05       Impact factor: 2.628

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.